HK inno.N is expanding the lineup of 'Akynzeo,' a medicine used to prevent vomiting in cancer patients. In addition to the capsule formulation currently covered by health insurance, the company has applied for reimbursement to the Health Insurance Review and Assessment Service (HIRA) for Akynzeo inj.

According to industry sources on the 17th, Akynzeo inj, approved in October 2022, has applied for HIRA review.

Akynzeo was introduced to South Korea by HK inno.N from the Swiss pharmaceutical company Helsinn. It is used for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.